Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)

Coronaviruses are enveloped viruses with an RNA genome. Carrageenans are sulfate polysaccharides synthesized by red algae. Studies conducted in adults and children with the common cold showed the effectiveness of the use of Carrageenan in nasal spray.
For decades, the antiviral action of Carrageenans has been described in numerous studies with different viruses that infect humans: herpes viruses types 1 and 2, human immunodeficiency virus, human papillomavirus, H1N1 influenza virus, dengue virus, rhinovirus, hepatitis A virus, and enteroviruses. Studies on the dynamics of COVID-19 disease show an intense and rapid pharyngeal multiplication in the first 3-5 days of the onset of symptoms, prior to the onset of pulmonary disease.
Finally, this molecule has shown a viricidal effect against SARS-Cov2 in vitro. All this underscores the potential value of a therapy that inhibits the virus in the rhinopharynx.

开始日期2020-07-24

申办/合作机构-

NCT03009799 / Withdrawn临床2期

Evaluation of the Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) Versus Placebo in Patients With Adenoviral Conjunctivis

This clinical investigation aims at demonstrating that NCX-4240 is effective and safe in decreasing the number of days where adenoviral conjunctivis is detected in the eye and in reducing the duration and/or the severity of the signs and symptoms of adenoviral conjunctivis

开始日期2017-01-01

申办/合作机构

Nicox SA

[+2]

100 项与 Iota-Carrageenan 相关的临床结果

登录后查看更多信息

100 项与 Iota-Carrageenan 相关的转化医学

登录后查看更多信息

100 项与 Iota-Carrageenan 相关的专利（医药）

登录后查看更多信息

143

项与 Iota-Carrageenan 相关的文献（医药）

2024-10-01·Ecotoxicology and Environmental Safety

Evaluation, optimization study, and life cycle assessment of novel eco-friendly PVA-based nanocomposite hydrogel adsorbents for methylene blue and paracetamol removal

Article

作者: Almahmoud, Sondos A.J. ; Elessawy, Noha A ; Almahmoud, Sondos A J ; Alhamzani, Abdulrahman G. ; Alhamzani, Abdulrahman G ; Elessawy, Noha A. ; Hsiao, Benjamin S. ; Hsiao, Benjamin S

In this study, an eco-friendly and novel hydrogel based on a crosslinked polyvinyl alcohol (PVA), iota carrageenan (IC) and polyvinylpyrrolidone (PVP) scaffold, containing a large amount (10-50 wt%) of nanoscale palm fronds (NPF) as additives, for water purification was demonstrated. A life cycle assessment (LCA) findings on NPF as biomass waste incorporated into PVA_PVP_IC polymer matrix was presented, and the results highlight the necessity of focused actions to reduce environmental impact and support the palm waste utilization in a sustainable manner. The multicomponent nanocomposite hydrogels were examined as adsorbents in a system work in batches for methylene blue (MB) and paracetamol (PCT) removal. The results show that, the presence of NPF, which dispersed in the hydrogel PVA_PVP_IC scaffolds containing both covalent and non-covalent cross-linking bonds, greatly enhanced the MB and PCT adsorption efficiency. A response surface methodology (RSM) model was used to find the best operating parameters of contaminant adsorption, including time, adsorbent dose, and starting concentration of pollutants. By using this statistical model, it was found that the optimal conditions for the adsorption reaction to achieve the complete removal of MB are 66.7 h adsorption time duration, 98.5 mg L^-1 starting concentration, and an adsorbent dose of 5.9 mg, while for the complete removal of PCT, it is 57.6 h adsorption time duration, 80 mg L^-1 starting concentration, and an adsorbent dose of 6 mg. The reusability of the nanocomposite hydrogels were tested for 5 cycles, all showed high adsorption capacity, indicating the potential for practical application of this nanocomposite hydrogel system. This study indicates that the prepared nanocomposite hydrogel raises the standard used for treatment of wastewater and also gives a solution to protect the environment and mitigate global warming.

2024-09-01·Sexually Transmitted Infections

Safety of carrageenan-based gels as preventive microbicides: a narrative review

Review

作者: Laurie, Cassandra ; Franco, Eduardo L ; El-Zein, Mariam

BackgroundCarrageenan-containing gels researched for the prevention of sexually transmitted infections (STIs) have shown promising results for human papillomavirus prevention in women, but not in men. We conducted a narrative review to assess the safety of these gels for genital use.MethodsWe searched PubMed using MeSH terms and keywords on 5 November 2023. Title/abstract of articles were screened to identify relevant ones. Full-text screening determined eligibility: empirical study evaluating safety of carrageenan-containing gel(s) for genital use.ResultsOf the 125 identified records, 15 were eligible, comprising 14 (10 randomised controlled trials and 4 cohorts) unique study populations. Studies included women only (n=11), men only (n=1) or both (n=3); number of participants ranged from 4 to 6202. Safety was assessed for vaginal (n=13), penile (n=3) and anal use (n=2). Most studies assessed safety of Carraguard (53%), followed by Divine9 (14%), and one each of iota-carrageenan gel, lambda-carrageenan gel, Carvir, PC-6500 (griffithsin and carrageenan) and PC-1005 (MIV-150/zinc acetate/carrageenan). Safety assessment relied on self-report (80.0%), testing for STIs (53.3%), investigator-identified genital findings (93.3%) and/or testing for changes in genital flora (60.0%). Adverse events (AEs) were described by investigators as mostly mild, (mostly) comparable between groups, not observed and/or not significant for vaginal and penile use. Only one study, assessing anal use of carrageenan, reported a significantly higher proportion of AEs in the carrageenan compared with placebo group.ConclusionsCarrageenan-based gels are generally well tolerated for vaginal and penile, but not anal use. Studies on carrageenan gel’s safety for anal use are scarce.

2024-06-17·ACS Applied Bio Materials

Electron Beam-Supported Fabrication of Biocompatible Silver/iota-Carrageenan for Wound Healing Application

Article

作者: Alagumalai, Krishnapandi ; Gupta, Vijai Kumar ; Raj, Vinit ; Gangadhar, Lekshmi ; Kaushik, Ajeet Kumar ; Raorane, Chaitany Jayprakash ; Sana, Siva Sankar ; Kim, Seong-Cheol

Silver nanoparticles (AgNPs) are a potent antibacterial agent, especially when used to treat bacteria that are multidrug resistant. However, it is challenging to eliminate the hazardous reducing agents that remain in AgNPs produced by the conventional chemical reduction process. To overcome these challenges, the presented research demonstrates the fabrication of AgNPs using iota-carrageenan (ι-carra) as a carbohydrate polymer using electron beam (EB) irradiation. Well-characterized ι-carra@AgNPs have a face-centered cubic (FCC) structure with spherical morphology and an average size of 26 nm. Herein we explored the approach for fabricating ι-carra@AgNPs that is suitable for scaling up the production of nanoparticles that exhibit excellent water stability. Further, the optimized ι-carra@AgNPs exhibited considerable antibacterial activity of 40% and 30% inhibition when tested with Gram-negative Escherichia coli ATCC 43895 and Gram-positive Staphylococcus aureus (S. aureus) (ATCC 6538), respectively, and low cytotoxicity at 10-50 μg/mL. To establish the potential biomedical application, as proof of the concept, the ι-carra@AgNPs showed significant antibiofilm activity at 20 μg/mL and also showed 95% wound healing abilities at 50 μg/mL compared to the nontreated control groups. Electron beam assisted ι-carra@AgNPs showed significant beneficial effects against specific bacterial strains and may provide a guide for the development of new antibacterial materials for wound dressing for large-scale production for biomedical applications.

项与 Iota-Carrageenan 相关的新闻（医药）

2021-11-16

·BioSpace

Amcyte Pharma Announces U.S. Launch of Nasitrol® Nasal Spray

Study Publication: Algae-Derived Nasal Spray Effective as Prophylaxis in Reducing COVID Infection Among ICU Staff KIRKLAND, WA – NOVEMBER 16, 2021 -- Amcyte Pharma, a Seattle-based company dedicated to the development of novel pharmaceutical products in immunology, announced the U.S. launch of its Nasitrol® nasal spray for sinus irrigation. In an independent clinical trial published in the peer-reviewed International Journal of General Medicine, Nasitrol reduced COVID transmission among ICU staff by nearly 80%, suggesting it could represent a safe and effective prophylaxis to prevent transmission of COVID-19. Nasitrol is a patented nasal spray based on iota carrageenan, a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as a nasal spray in the treatment of the common cold. The nasal cavity and the rhinopharynx are key sites of the initial replication of SARS-CoV-2. Iota-carrageenan is thought to exert antiviral activity through its interaction with the viral surface, preventing viral entry and capturing viral particles released by infected cells. Nasitrol is designed to reduce the viral load in upper respiratory airways, preventing viruses from proliferating and spreading into the lungs. “We are excited to be commercializing Nasitrol nasal spray, a product that has shown such promise as a prophylaxis against COVID transmission, in addition to vaccination, hand hygiene, use of personal protective equipment and social distancing,” said Dr. Gustavo Mahler, CEO of Amcyte Pharma. The clinical study was conducted at 8 hospital ICUs with a sample of 394 clinically healthy physicians, nurses and other medical professionals who provided care to COVID patients and who had not yet been vaccinated. Study subjects were randomly assigned to receive four daily doses of Nasitrol spray or placebo for 21 days. The incidence of COVID-19 infection, as detected with PCR testing, was significantly lower in the Nasitrol group compared with placebo (1.0% vs 5.0%), a reduction in risk of 79.8%. The study was led by Dr. Juan M. Figueroa of The Cesar Milstein Research Institute in Argentina. Nasitrol is the only nasal spray based on iota carrageenan available in the US. Nasitrol is available through the company’s web site or by contacting the company at (800) 217-0441 or info@nasitrol.com. About Amcyte Pharma Amcyte’s team has over 20 years of experience in pharmaceutical development and manufacturing. The company has built strong partnerships with leading academic institutions and clinical groups to develop novel indications for its portfolio of products. Amcyte’s pipeline includes over-the-counter products with improved therapeutic profiles against existing treatments. For more information, please visit .

疫苗

100 项与 Iota-Carrageenan 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15304

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新型冠状病毒感染	申请上市	美国	AmCyte, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2016	N/A	感染性角结膜炎	-	NCX4240 (iota-carrageenan) eye drops	選選糧淵觸糧築積鑰鹹(糧廠壓夢壓鬱願製積鏇) = 窪願遞選繭鏇壓醖鹹鹹艱製築廠選顧獵網顧顧 (鏇築構鹽願鬱艱鑰襯糧 )	-	2016-05-01
				Vismed© (hyaluronic acid) eye drops	選選糧淵觸糧築積鑰鹹(糧廠壓夢壓鬱願製積鏇) = 醖淵齋廠鬱鹹積夢憲蓋艱製築廠選顧獵網顧顧 (鏇築構鹽願鬱艱鑰襯糧 )